The effect of oral diacerein in relieving symptoms of knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069578

Enrollment

Unknown

Registered

2023-03-21

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

study group:Oral diacarine,50mg/ time, twice/day for 12 weeks

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Voluntary signing of informed consent; (2) Age: 40-75 years old; (3) Meet the diagnostic criteria of the American College of Rheumatology (ACR) for knee osteoarthritis; (4) Mild to moderate OA with Kellgren-Lawrence scale grade 1 to grade 3, and pain degree = 40mm (VAS).

Exclusion criteria

Exclusion criteria: (1) Allergic to drug ingredients; (2) A history of diacerein use in the last 2 weeks; (3) Other complications or joint diseases (e.g., suppurative arthritis, gout, rheumatoid arthritis and ankylosing spondylitis); (4) The presence of other diseases that may cause knee pain (such as bone tumors, fractures, etc.); (5) Pregnant or breastbreeding.

Design outcomes

Primary

Measure	Time frame
WOMAC Pain score;VAS pain score;	—

Secondary

Measure	Time frame
WOMAC feature rating;WOMAC stiffness score;	—

Countries

China

Contacts

Public ContactWenfeng Xiao

Xiangya Hospital Central South University

xiaowenfeng@csu.edu.cn+86 13787043132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026